Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own3.00% Shs Outstand7.00M Perf Week-0.56%
Market Cap39.16M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float5.61M Perf Month-27.31%
Income-17.40M PEG- EPS next Q-0.40 Inst Own34.70% Short Float0.38% Perf Quarter-5.14%
Sales52.60M P/S0.74 EPS this Y36.50% Inst Trans27.00% Short Ratio1.38 Perf Half Y-9.93%
Book/sh-4.51 P/B- EPS next Y69.20% ROA-32.10% Target Price12.67 Perf Year13.83%
Cash/sh1.08 P/C4.96 EPS next 5Y- ROE70.20% 52W Range3.94 - 7.92 Perf YTD4.29%
Dividend- P/FCF- EPS past 5Y-1.10% ROI5.30% 52W High-32.32% Beta1.37
Dividend %- Quick Ratio1.20 Sales past 5Y11.40% Gross Margin85.70% 52W Low36.04% ATR0.36
Employees145 Current Ratio1.30 Sales Q/Q-32.70% Oper. Margin-20.50% RSI (14)34.86 Volatility5.35% 5.24%
OptionableNo Debt/Eq- EPS Q/Q-143.30% Profit Margin-33.00% Rel Volume0.06 Prev Close5.35
ShortableYes LT Debt/Eq- EarningsJul 27 BMO Payout- Avg Volume15.32K Price5.36
Recom2.00 SMA20-13.28% SMA50-15.35% SMA200-1.57% Volume209 Change0.19%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Sep-23-22 08:00AM
Sep-20-22 08:00AM
Sep-19-22 09:40AM
Sep-02-22 09:40AM
Aug-31-22 08:48AM
Aug-29-22 08:50AM
Aug-19-22 08:50AM
Aug-17-22 09:40AM
Aug-10-22 08:00AM
Aug-09-22 08:00AM
Aug-05-22 08:50AM
Aug-01-22 09:40AM
Jul-27-22 08:45AM
Jul-26-22 08:00AM
Jul-22-22 10:34AM
Jul-13-22 08:00AM
Jul-08-22 08:00AM
Jun-24-22 07:10AM
Jun-08-22 08:03AM
Jun-02-22 08:00AM
May-12-22 08:03AM
May-09-22 09:15AM
May-06-22 08:00AM
May-05-22 05:55PM
Apr-28-22 08:30AM
Apr-26-22 07:24AM
Apr-06-22 08:00AM
Mar-31-22 08:15AM
Mar-30-22 05:44AM
Mar-28-22 10:48AM
Mar-02-22 08:00AM
Mar-01-22 08:35AM
Feb-24-22 09:25AM
Feb-23-22 08:00AM
Feb-17-22 08:00AM
Feb-07-22 08:00AM
Feb-04-22 08:00AM
Jan-28-22 10:07AM
Jan-05-22 08:00AM
Dec-01-21 07:30AM
Nov-09-21 01:16PM
Nov-06-21 08:15AM
Nov-05-21 10:03AM
Oct-28-21 06:01PM
Oct-21-21 08:00AM
Oct-20-21 03:02PM
Oct-13-21 08:00AM
Sep-02-21 04:30PM
Aug-24-21 08:00AM
Aug-13-21 12:00PM
Aug-10-21 08:00AM
Aug-09-21 08:00AM
Jul-28-21 03:03PM
Jun-05-21 04:22AM
May-27-21 07:15PM
May-17-21 08:12AM
Apr-29-21 03:30PM
Apr-28-21 07:25PM
Apr-26-21 10:51AM
Apr-22-21 08:00AM
Apr-14-21 10:34AM
Apr-09-21 08:00AM
Mar-18-21 08:00AM
Mar-17-21 08:00AM
Mar-11-21 08:00AM
Mar-02-21 08:00AM
Feb-25-21 03:30PM
Feb-24-21 04:05PM
Feb-18-21 10:57AM
Feb-17-21 08:30AM
Feb-15-21 08:30AM
Feb-01-21 09:05AM
Jan-19-21 08:00AM
Jan-05-21 08:00AM
Dec-24-20 09:14AM
Dec-22-20 10:22AM
Dec-21-20 10:13AM
Dec-17-20 08:42AM
Dec-16-20 01:31PM
Dec-15-20 09:57AM
Dec-14-20 12:59PM
Dec-11-20 08:34AM
Dec-10-20 09:40AM
Dec-09-20 08:33AM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORGAN STANLEY10% OwnerFeb 08Sale4.55250,0001,137,500557,551Feb 10 09:11 PM
EISWIRTH RICHARD S JRPresident and CEODec 15Buy4.504842,177110,518Dec 16 07:36 AM
EISWIRTH RICHARD S JRPresident and CEODec 03Buy4.805,00023,981110,034Dec 07 10:33 AM
EISWIRTH RICHARD S JRPresident and CEODec 02Buy4.895,00024,428105,034Dec 06 11:24 AM
EISWIRTH RICHARD S JRPresident and CEONov 05Buy5.501,4007,700100,034Nov 08 04:01 PM
EISWIRTH RICHARD S JRPresident and CEONov 04Buy4.4110,08644,44698,634Nov 08 04:01 PM
Largent James RDirectorNov 03Buy4.3110,00043,09013,000Nov 04 08:09 PM
Jones John PhilipChief Financial OfficerNov 03Buy4.085,00020,39924,965Nov 04 04:50 PM
EISWIRTH RICHARD S JRPresident and CEONov 03Buy4.4528,005124,74588,548Nov 04 04:43 PM
Holland DavidChief Marketing Officer & SVPNov 03Buy4.085,00020,39131,130Nov 04 04:31 PM